Advanced Malignant Solid Tumors
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Advanced Malignant Solid Tumors is an early-stage landscape with 8 programs across 32 companies. The most active players are Hefei Xinzhu Biological Technology Co., Ltd., Merck & Co., Pfizer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Hefei Xinzhu Biological Technology Co., Ltd.
3 programs
Merck & Co.
1 program
Pfizer
0 programs
FindCure Biosciences (ZhongShan) Co., Ltd.
0 programs
Chongqing Precision Biotech Co., Ltd
0 programs
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
0 programs
Pipeline
Programs by Phase
Analysis
Modality Breakdown
60%
Small molecule
3 of 5 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 63% of 8 pipeline programs.
Analysis
Trial Status
81
clinical trials
Clinical Trials
Trial Activity
81 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)